Damora Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GLTO research report →
About the company
Damora Therapeutics, Inc. , a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
- CEO
- Jennifer A. Jarrett
- IPO
- 2020
- Employees
- 7
- HQ
- Boston, MA, US
Price Chart
- Market Cap
- $34.47M
- P/E
- -0.19
- P/S
- 0.00
- P/B
- 2.02
- EV/EBITDA
- -5.59
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -122.61%
- ROIC
- -46.73%
- Revenue
- $0 · 0.00%
- Net Income
- $-209,839,000 · -878.77%
- EPS
- $-3.71 · 79.98%
- Op Income
- $-210,872,000
- FCF YoY
- 63.88%
- 52W High
- $38.33
- 52W Low
- $2.01
- 50D MA
- $26.12
- 200D MA
- $13.34
- Beta
- 1.60
- Avg Volume
- 480.39K
Get TickerSpark's AI analysis on GLTO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 9, 26 | Bruno Julianne | other | 129,000 |
| Feb 9, 26 | Bruno Julianne | other | 129 |
| Feb 9, 26 | Fairmount Funds Management LLC | other | 5,809,000 |
| Feb 9, 26 | Fairmount Funds Management LLC | other | 2,904,000 |
| Feb 9, 26 | Fairmount Funds Management LLC | other | 5,809 |
| Feb 9, 26 | Fairmount Funds Management LLC | other | 2,904 |
| Jan 5, 26 | Sattarzadeh Sherwin | other | 444,209 |
| Jan 5, 26 | Sattarzadeh Sherwin | other | 190,376 |
| Jan 5, 26 | Sattarzadeh Sherwin | other | 0 |
| Jan 5, 26 | Hewes L. Becker | other | 528,603 |
Our GLTO coverage
Recent articles, reports, and earnings notes.
No research on GLTO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GLTO report →Similar companies
Peers in the same neighborhood.